




RealRate

PHARMACEUTICAL 2020

AGIOS PHARMACEUTICALS INC.
Rank 175 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

The relative strengths and weaknesses of AGIOS PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AGIOS PHARMACEUTICALS INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 64% points. The greatest weakness of AGIOS PHARMACEUTICALS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 123% points.

The company's Economic Capital Ratio, given in the ranking table, is -168%, being 134% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	611,704
Cost of Goods Sold	1,317
Intangible Assets	0
Liabilities, Current	92,886
Liabilities, Non-Current	156,654
Other Assets	247,565
Other Compr. Net Income	2,373
Other Expenses	0
Other Liabilities	673
Other Net Income	14,861
Property and Equipment	31,472
Research and Development	410,894
Revenues	117,912
Selling, General and Administrative Expense	132,034

Output Variable	Value in 1000 USD
Assets	890,741
Liabilities	250,213
Expenses	544,245
Stockholders Equity	640,528
Net Income	-411,472
Comprehensive Net Income	-410,286
Economic Capital Ratio	-168%